Most Recent

image: Doors and Pores

Doors and Pores

By | December 1, 2016

The awesome architecture of the gateways to the nucleus

0 Comments

image: An Evolutionary History

An Evolutionary History

By | October 1, 2016

Celebrating 30 years and a resurrection

2 Comments

image: Transparency Now

Transparency Now

By | May 1, 2016

Science is messy. So lay it out, warts and all.

1 Comment

image: Things That Go Bump

Things That Go Bump

By | March 1, 2016

Scientists still don’t know why animals sleep or how to define the ubiquitous behavior.

2 Comments

image: Special Delivery

Special Delivery

By | October 1, 2015

Neurons in new brains and old

0 Comments

image: Intelligence Gathering

Intelligence Gathering

By | July 1, 2015

Disease eradication in the 21st century

0 Comments

image: Hiding in the Haystack

Hiding in the Haystack

By | May 1, 2015

Encouraging developments in HIV research

0 Comments

image: Bad Raps

Bad Raps

By | December 1, 2014

Understanding animal diseases—for their sake and for ours

0 Comments

image: Head Scratchers

Head Scratchers

By | September 1, 2014

Many natural phenomena elude our understanding.

5 Comments

image: Small Packages

Small Packages

By | August 1, 2014

When proverbs come true

0 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham